<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> is thought to be a complication of severe <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">gastro-oesophageal reflux</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>AIM: To determine whether the <z:chebi fb="0" ids="49200">proton pump inhibitor</z:chebi>, <z:chebi fb="0" ids="6375">lansoprazole</z:chebi>, is effective in healing erosive <z:e sem="disease" ids="C0677659,C0014869" disease_type="Disease or Syndrome" abbrv="">reflux oesophagitis</z:e> in patients with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: An 8-week, randomized, double-blind study was conducted using patients with both erosive <z:e sem="disease" ids="C0677659,C0014869" disease_type="Disease or Syndrome" abbrv="">reflux oesophagitis</z:e> and <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Erosive <z:e sem="disease" ids="C0677659,C0014869" disease_type="Disease or Syndrome" abbrv="">reflux oesophagitis</z:e> was defined as grades 2-4 oesophagitis; <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e>, as specialized columnar epithelium obtained by biopsy from the tubular oesophagus; and healing, as a return to grade 0 or 1 oesophageal mucosa (complete re-epithelialization) </plain></SENT>
<SENT sid="4" pm="."><plain>One-hundred and five (105) patients from one centre were randomized to receive either <z:chebi fb="0" ids="6375">lansoprazole</z:chebi> 30 mg daily or <z:chebi fb="10" ids="8776">ranitidine</z:chebi> 150 mg twice daily </plain></SENT>
<SENT sid="5" pm="."><plain>Unhealed or symptomatic <z:chebi fb="0" ids="6375">lansoprazole</z:chebi> patients at week 4 were randomized to receive the same 30 mg dose daily or an increased dose of 60 mg daily </plain></SENT>
<SENT sid="6" pm="."><plain>Endoscopy was performed at baseline and at weeks 2, 4, 6 and 8 </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: The treatment groups were similar in regards to baseline characteristics, erosive <z:e sem="disease" ids="C0677659,C0014869" disease_type="Disease or Syndrome" abbrv="">reflux oesophagitis</z:e> grades and length of <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>At each 2-week interval, <z:chebi fb="0" ids="6375">lansoprazole</z:chebi> patients had significantly greater healing rates and less day and night heartburn and regurgitation than <z:chebi fb="10" ids="8776">ranitidine</z:chebi> patients </plain></SENT>
<SENT sid="9" pm="."><plain>There were no significant differences between treatment groups in antacid use, quality of life parameters, or rate of reported adverse events </plain></SENT>
<SENT sid="10" pm="."><plain>Median values for fasting serum gastrin levels remained within the <z:mpath ids='MPATH_458'>normal</z:mpath> range for both groups </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: In patients with both <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> and erosive <z:e sem="disease" ids="C0677659,C0014869" disease_type="Disease or Syndrome" abbrv="">reflux oesophagitis</z:e>, <z:chebi fb="0" ids="6375">lansoprazole</z:chebi> is significantly more effective than <z:chebi fb="10" ids="8776">ranitidine</z:chebi> in relieving reflux symptoms and healing erosive <z:e sem="disease" ids="C0677659,C0014869" disease_type="Disease or Syndrome" abbrv="">reflux oesophagitis</z:e> </plain></SENT>
</text></document>